Study wrapper · #57
From Selye's and Szabo's Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities.
Editor's note
Here BPC-157 is a minor player, not the subject: this review is chiefly about dopamine and gastric ulcer healing, discussing dopamine agonists and antagonists and the cysteamine ulcer model. BPC-157 is mentioned among several peptides (alongside amylin, cholecystokinin and leptin) as a possible mediator of the dopamine brain-gut axis. That distinction matters, this paper does not test or demonstrate any BPC-157 effect; it references it in passing within a broader pharmacology discussion. Readers should not take its inclusion as evidence of efficacy. The wider BPC-157 literature remains preclinical, and human data are needed for any clinical conclusion. BPC-157 is not FDA-approved and was removed from the FDA Category-2 compounding list.
Plain-language abstract
This review is mainly about dopamine, a brain chemical, and its role in healing stomach and duodenal ulcers. The authors trace research showing that drugs which boost dopamine tend to protect against ulcers, while drugs that block it can promote them, using a classic chemically-induced ulcer model in rats. Toward the end, they mention several peptides that might interact with the dopamine system connecting the brain and gut, and BPC-157 is one of them, listed alongside others like leptin. BPC-157 is only a passing reference here, not the focus, and the review does not test it or show any effect from it. So while the peptide appears in this paper, that appearance does not add evidence that it works for anything.